Lycia Therapeutics, Inc. Common Stock (NASDAQ:LYCA)
| Market Cap | 1.56B+0.0% |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 52.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,280,584 |
| Open | 28.55 |
| Previous Close | 18.00 |
| Day's Range | 22.19 - 36.27 |
| 52-Week Range | 22.19 - 36.49 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About LYCA
Lycia Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory, and allergic diseases. The company was founded in 2019 and is headquartered in South San Francisco, CA.
$LYCA stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in LYCA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by LYCA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
LYCA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New LYCA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to LYCA from public contracts
Source: USAspending.gov
LYCA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from LYCA’s recent data — informational, not investment advice
Recent Insider Activity
No Form 4 filings in the last 90 days.